{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.2","upperLimit":"98.8","value":"96.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"description":"EFS is defined as the time from on study to failure to achieve hematological CR prior to start of consolidation, persistence of molecular positive disease after MRD positive consolidation course, relapse (molecular, morphologic or extramedullary), or death. The Kaplan-Meier method will be used to estimate 2-year EFS along with 90% log-minus-log transformed confidence limits.","dispersionType":"90% Confidence Interval","groups":[{"description":"WBC ≥10,000 cells/µL","id":"OG000","title":"High Risk"}],"paramType":"NUMBER","populationDescription":"Patients ineligible, did not start treatment, or RQPCR positive not confirmed are excluded from analyses of EFS","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"EFS in High Risk APL Patients","type":"PRIMARY","unitOfMeasure":"percentage of participants"}